AB Science S.A. (OTCMKTS:ABSCF) Sees Significant Increase in Short Interest

AB Science S.A. (OTCMKTS:ABSCF) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 1,500 shares, a growth of 200.0% from the December 31st total of 500 shares. Based on an average daily volume of 300 shares, the short-interest ratio is currently 5.0 days.

AB Science Price Performance

Shares of ABSCF remained flat at $0.90 on Thursday. AB Science has a 12 month low of $0.80 and a 12 month high of $1.06. The firm has a 50 day moving average of $0.92 and a two-hundred day moving average of $1.14.

AB Science Company Profile

AB Science SA, a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19.